aceto sells generic prescription products and over-the-counter pharmaceutical products to leading wholesalers , chain drug stores , distributors and mass merchandisers . on december 21 , 2016 , wholly owned subsidiaries of rising pharmaceuticals , inc. ( “ rising ” ) , a wholly owned subsidiary of aceto , completed the acquisition of certain generic products and related assets of entities formerly known as citron pharma llc ( “ citron ” ) and its affiliate lucid pharma llc ( “ lucid ” ) . citron was a privately-held new jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in india and the united states . lucid was a privately-held new jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the u.s. federal government including the veterans administration and the defense logistics agency . lucid serviced 18 national contracts with the federal government . rising formed two subsidiaries to consummate the product acquisition – rising health , llc ( which acquired certain products and related assets of citron ) and acetris health , llc ( which acquired certain products and related assets of lucid ) . the assets acquired in the product purchase transaction expanded , complemented , and strengthened our existing and future product offerings . in what has become a competitive generic drug business environment , one key for long-term success is having an ever-growing commercial portfolio of generic products , a strong internal drug development pipeline and capable , reliable manufacturing partners . we believe that this transaction added significantly to the rising business platform in all three crucial areas . we also believe that , consistent with our strategy of expanding our portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets , abbreviated new drug applications ( “ andas ” ) and complementary generic drug businesses , this product acquisition significantly expanded our roster of commercialized products and pipeline of products under development . based on a report issued by iqvia institute on april 19 , 2018 , “ spending on medicines grew by 0.6 % in 2017 after off-invoice discounts and rebates . this spending includes all types of medicines , including institutional use for inpatients and outpatients . focusing only on retail and mail-order pharmacy distribution , net spending declined by 2.1 % . ” during the third quarter of fiscal 2018 , our rising pharmaceuticals reporting unit had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market . in addition , in february 2018 , we were notified by the u.s. government that 11 generic drug products we acquired through our acetris health subsidiary are not in compliance with the federal trade agreement act country-of-origin provisions of a clause contained in the government supply contracts acquired from lucid . based on these indicators , we determined that it was necessary to perform an interim goodwill impairment analysis at march 31 , 2018 for our rising reporting unit . accordingly , we recognized pre-tax non-cash impairment charges of $ 256,266 consisting of $ 235,110 of a goodwill impairment charge and a $ 21,156 write-down of other identifiable intangible assets . aceto also supplies the raw materials used in the production of nutritional and packaged dietary supplements , including vitamins , amino acids , iron compounds and biochemicals used in pharmaceutical and nutritional preparations . the pharmaceutical ingredients segment has two product groups : active pharmaceutical ingredients ( apis ) and pharmaceutical intermediates . 34 we supply apis to many of the major generic drug companies , who we believe view aceto as a valued partner in their effort to develop and market generic drugs . the process of introducing a new api from pipeline to market spans a number of years and begins with aceto partnering with a generic pharmaceutical manufacturer and jointly selecting an api , several years before the expiration of a composition of matter patent , for future genericizing . we then identify the appropriate supplier , and concurrently utilizing our global technical network , work to ensure they meet standards of quality to comply with regulations . our client , the generic pharmaceutical company , will submit the anda for u.s. food and drug administration ( “ fda ” ) approval or european-equivalent approval . the introduction of the api to market occurs after all the development testing has been completed and the anda or european-equivalent is approved and the patent expires or is deemed invalid . aceto , at all times , has a pipeline of apis at various stages of development both in the united states and europe . additionally , as the pressure to lower the overall cost of healthcare increases , aceto has focused on , and works very closely with our customers to develop new api opportunities to provide alternative , more economical , second-source options for existing generic drugs . by leveraging our worldwide sourcing , regulatory and quality assurance capabilities , we provide to generic drug manufacturers an alternative , economical source for existing api products . aceto has long been a supplier of pharmaceutical intermediates , the complex chemical compounds that are the building blocks used in producing apis . these are the critical components of all drugs , whether they are already on the market or currently undergoing clinical trials . faced with significant economic pressures as well as ever-increasing regulatory barriers , the innovative drug companies look to aceto as a source for high quality intermediates . aceto employs , on occasion , the same second source strategy for our pharmaceutical intermediates business that we use in our api business . historically , pharmaceutical manufacturers have had one source for the intermediates needed to produce their products . story_separator_special_tag the company elected to early adopt accounting standards update ( “ asu ” ) 2017-04 , intangibles- goodwill and other ( topic 350 ) , during the third quarter of fiscal 2018 which eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge . instead , the amount of an impairment charge is recognized if the carrying amount of a reporting unit is greater than its fair value . the fair value of the rising reporting unit was estimated using many assumptions and estimates and a market participant approach that directly impacts the results of the testing . in making these assumptions and estimates , the company used industry accepted valuation models and set criteria that were reviewed and approved by various levels of management . accordingly , with respect to the third quarter of fiscal 2018 , the company recognized a pre-tax non-cash goodwill impairment charge of $ 235,110 related to the rising reporting unit . long-lived assets long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . if it is determined such indicators are present and the review indicates that the assets will not be fully recoverable , based on undiscounted estimated cash flows over the remaining amortization periods , their carrying values are reduced to estimated fair value . measurements based on undiscounted cash flows are level 3 inputs . as noted above , during the third quarter of fiscal 2018 , the company 's rising pharmaceuticals subsidiary had a decline in actual and forecasted revenue and earnings and therefore the company performed an impairment test on the related intangibles . the projected undiscounted cash flows for certain intangibles were determined to be less than the carrying value , and as a result , the company recognized an impairment charge of $ 5,745 in the third quarter of fiscal 2018. additionally , as noted above , the company was notified by the u.s. government that 11 generic drug products it acquired through its acetris health subsidiary in a product purchase agreement with an entity formerly known as lucid pharma llc were not in compliance with the federal trade agreement act country-of-origin provisions of a clause contained in the government supply contracts acquired from lucid . based on this , the company performed an impairment test on the related intangible asset and recognized an impairment charge of $ 15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018 . 38 environmental and other contingencies we establish accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability can reasonably be estimated . if the contingency is resolved for an amount greater or less than the accrual , or our share of the contingency increases or decreases , or other assumptions relevant to the development of the estimate were to change , we would recognize an additional expense or benefit in income in the period that the determination was made . taxes we account for income taxes in accordance with gaap . gaap establishes financial accounting and reporting standards for the effects of income taxes that result from an enterprise 's activities during the current and preceding years . it requires an asset-and-liability approach to financial accounting and reporting of income taxes . deferred tax assets are recorded for net operating losses and temporary differences between the book and tax basis of assets and liabilities expected to produce tax deductions in future periods . the ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the tax periods in which those deferred tax assets would be deductible . a valuation allowance is taken when necessary to reduce deferred tax assets to the amount expected to be realized . when determining the amount of net deferred tax assets that are more likely than not to be realized , we assess all available positive and negative evidence . this evidence includes , but is not limited to , scheduled reversal of deferred tax liabilities , prior earnings history , projected future earnings , carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset . the weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified . as such , it is generally difficult for positive evidence regarding projected future taxable income ( exclusive of reversing taxable temporary differences and carryforwards ) to outweigh objective negative evidence such as our recent financial reporting loss for the year ended june 30 , 2018. therefore , we recorded a valuation allowance of $ 76,500 against our net u.s. deferred tax assets during the year ended june 30 , 2018. the timing of when , and the extent to which , a valuation allowance is recognized , is subjective . initially , due to the various factors that occurred in the fourth quarter of fiscal 2018 , including substantial penalties for delays in supplying products and incurring substantial expenses to address the issues that led to the impairment charges taken during the year , as well as retaining financial and legal advisors to assist us in dealing with the various challenges that the company is currently facing , including legal advisors retained in connection with various ongoing legal proceedings , we determined to record this valuation allowance during the fourth quarter of fiscal 2018. however , after weighing the information available to us at the time that our third quarter financial statements were issued , we have determined , with the assistance of our advisors , that it is reasonable to conclude that it was more likely than not that a substantial portion of the valuation allowance should have been

cash flows at june 30 , 2018 , we had $ 100,874 in cash , of which $ 21,269 was outside the united states , $ 3,030 in short-term investments , all of which is held outside the united states and $ 317,398 in debt ( including the current portion ) , all of which is an obligation in the united states . the $ 21,269 of cash held outside of the united states is fully accessible to meet any liquidity needs of the countries in which we operate . the majority of the cash located outside of the united states is held by our european and chinese operations and can be transferred into the united states . although these amounts are fully accessible , transferring these amounts into the united states or any other countries could have certain local tax consequences . in accordance with the tcja , we recorded $ 2,445 of additional income tax expense related to deferred tax liabilities for local tax authorities as we no longer assert permanent reinvestment of our undistributed non-u.s. subsidiaries ' earnings . a portion of our cash is held in operating accounts that are with third party financial institutions . while we monitor daily the cash balances in our operating accounts and adjust the cash balances as appropriate , these cash balances could be impacted if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets . to date , we have experienced no loss or lack of access to cash in our operating accounts . while significant demands on our cash persist , our cash position at june 30 , 2018 increased $ 45,194 from the amount at june 30 , 2017. operating activities for the year ended june 30 , 2018 provided cash of $ 101,806 for this period , as compared to cash provided of $ 44,567 for the prior year . the $ 101,806 resulted from a net loss of $ 316,121 offset by $ 315,460 derived from adjustments for non-cash items plus a net $ 102,467 increase from changes in operating assets and liabilities .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows at june 30 , 2018 , we had $ 100,874 in cash , of which $ 21,269 was outside the united states , $ 3,030 in short-term investments , all of which is held outside the united states and $ 317,398 in debt ( including the current portion ) , all of which is an obligation in the united states . the $ 21,269 of cash held outside of the united states is fully accessible to meet any liquidity needs of the countries in which we operate . the majority of the cash located outside of the united states is held by our european and chinese operations and can be transferred into the united states . although these amounts are fully accessible , transferring these amounts into the united states or any other countries could have certain local tax consequences . in accordance with the tcja , we recorded $ 2,445 of additional income tax expense related to deferred tax liabilities for local tax authorities as we no longer assert permanent reinvestment of our undistributed non-u.s. subsidiaries ' earnings . a portion of our cash is held in operating accounts that are with third party financial institutions . while we monitor daily the cash balances in our operating accounts and adjust the cash balances as appropriate , these cash balances could be impacted if the underlying financial institutions fail or are subject to other adverse conditions in the financial markets . to date , we have experienced no loss or lack of access to cash in our operating accounts . while significant demands on our cash persist , our cash position at june 30 , 2018 increased $ 45,194 from the amount at june 30 , 2017. operating activities for the year ended june 30 , 2018 provided cash of $ 101,806 for this period , as compared to cash provided of $ 44,567 for the prior year . the $ 101,806 resulted from a net loss of $ 316,121 offset by $ 315,460 derived from adjustments for non-cash items plus a net $ 102,467 increase from changes in operating assets and liabilities .
```    
 Suspicious Activity Report : aceto sells generic prescription products and over-the-counter pharmaceutical products to leading wholesalers , chain drug stores , distributors and mass merchandisers . on december 21 , 2016 , wholly owned subsidiaries of rising pharmaceuticals , inc. ( “ rising ” ) , a wholly owned subsidiary of aceto , completed the acquisition of certain generic products and related assets of entities formerly known as citron pharma llc ( “ citron ” ) and its affiliate lucid pharma llc ( “ lucid ” ) . citron was a privately-held new jersey-based pharmaceutical company focused on developing and marketing generic pharmaceutical products in partnership with leading generic pharmaceutical manufacturers based in india and the united states . lucid was a privately-held new jersey-based generic pharmaceutical distributor specializing in providing cost-effective products to various agencies of the u.s. federal government including the veterans administration and the defense logistics agency . lucid serviced 18 national contracts with the federal government . rising formed two subsidiaries to consummate the product acquisition – rising health , llc ( which acquired certain products and related assets of citron ) and acetris health , llc ( which acquired certain products and related assets of lucid ) . the assets acquired in the product purchase transaction expanded , complemented , and strengthened our existing and future product offerings . in what has become a competitive generic drug business environment , one key for long-term success is having an ever-growing commercial portfolio of generic products , a strong internal drug development pipeline and capable , reliable manufacturing partners . we believe that this transaction added significantly to the rising business platform in all three crucial areas . we also believe that , consistent with our strategy of expanding our portfolio of finished dosage form generic products through product development partnerships and acquisitions of late stage assets , abbreviated new drug applications ( “ andas ” ) and complementary generic drug businesses , this product acquisition significantly expanded our roster of commercialized products and pipeline of products under development . based on a report issued by iqvia institute on april 19 , 2018 , “ spending on medicines grew by 0.6 % in 2017 after off-invoice discounts and rebates . this spending includes all types of medicines , including institutional use for inpatients and outpatients . focusing only on retail and mail-order pharmacy distribution , net spending declined by 2.1 % . ” during the third quarter of fiscal 2018 , our rising pharmaceuticals reporting unit had a decline in actual and forecasted revenue and earnings due to the persistent adverse conditions in the generics market . in addition , in february 2018 , we were notified by the u.s. government that 11 generic drug products we acquired through our acetris health subsidiary are not in compliance with the federal trade agreement act country-of-origin provisions of a clause contained in the government supply contracts acquired from lucid . based on these indicators , we determined that it was necessary to perform an interim goodwill impairment analysis at march 31 , 2018 for our rising reporting unit . accordingly , we recognized pre-tax non-cash impairment charges of $ 256,266 consisting of $ 235,110 of a goodwill impairment charge and a $ 21,156 write-down of other identifiable intangible assets . aceto also supplies the raw materials used in the production of nutritional and packaged dietary supplements , including vitamins , amino acids , iron compounds and biochemicals used in pharmaceutical and nutritional preparations . the pharmaceutical ingredients segment has two product groups : active pharmaceutical ingredients ( apis ) and pharmaceutical intermediates . 34 we supply apis to many of the major generic drug companies , who we believe view aceto as a valued partner in their effort to develop and market generic drugs . the process of introducing a new api from pipeline to market spans a number of years and begins with aceto partnering with a generic pharmaceutical manufacturer and jointly selecting an api , several years before the expiration of a composition of matter patent , for future genericizing . we then identify the appropriate supplier , and concurrently utilizing our global technical network , work to ensure they meet standards of quality to comply with regulations . our client , the generic pharmaceutical company , will submit the anda for u.s. food and drug administration ( “ fda ” ) approval or european-equivalent approval . the introduction of the api to market occurs after all the development testing has been completed and the anda or european-equivalent is approved and the patent expires or is deemed invalid . aceto , at all times , has a pipeline of apis at various stages of development both in the united states and europe . additionally , as the pressure to lower the overall cost of healthcare increases , aceto has focused on , and works very closely with our customers to develop new api opportunities to provide alternative , more economical , second-source options for existing generic drugs . by leveraging our worldwide sourcing , regulatory and quality assurance capabilities , we provide to generic drug manufacturers an alternative , economical source for existing api products . aceto has long been a supplier of pharmaceutical intermediates , the complex chemical compounds that are the building blocks used in producing apis . these are the critical components of all drugs , whether they are already on the market or currently undergoing clinical trials . faced with significant economic pressures as well as ever-increasing regulatory barriers , the innovative drug companies look to aceto as a source for high quality intermediates . aceto employs , on occasion , the same second source strategy for our pharmaceutical intermediates business that we use in our api business . historically , pharmaceutical manufacturers have had one source for the intermediates needed to produce their products . story_separator_special_tag the company elected to early adopt accounting standards update ( “ asu ” ) 2017-04 , intangibles- goodwill and other ( topic 350 ) , during the third quarter of fiscal 2018 which eliminated the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge . instead , the amount of an impairment charge is recognized if the carrying amount of a reporting unit is greater than its fair value . the fair value of the rising reporting unit was estimated using many assumptions and estimates and a market participant approach that directly impacts the results of the testing . in making these assumptions and estimates , the company used industry accepted valuation models and set criteria that were reviewed and approved by various levels of management . accordingly , with respect to the third quarter of fiscal 2018 , the company recognized a pre-tax non-cash goodwill impairment charge of $ 235,110 related to the rising reporting unit . long-lived assets long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable . if it is determined such indicators are present and the review indicates that the assets will not be fully recoverable , based on undiscounted estimated cash flows over the remaining amortization periods , their carrying values are reduced to estimated fair value . measurements based on undiscounted cash flows are level 3 inputs . as noted above , during the third quarter of fiscal 2018 , the company 's rising pharmaceuticals subsidiary had a decline in actual and forecasted revenue and earnings and therefore the company performed an impairment test on the related intangibles . the projected undiscounted cash flows for certain intangibles were determined to be less than the carrying value , and as a result , the company recognized an impairment charge of $ 5,745 in the third quarter of fiscal 2018. additionally , as noted above , the company was notified by the u.s. government that 11 generic drug products it acquired through its acetris health subsidiary in a product purchase agreement with an entity formerly known as lucid pharma llc were not in compliance with the federal trade agreement act country-of-origin provisions of a clause contained in the government supply contracts acquired from lucid . based on this , the company performed an impairment test on the related intangible asset and recognized an impairment charge of $ 15,411 on the customer relationships intangible asset in the third quarter of fiscal 2018 . 38 environmental and other contingencies we establish accrued liabilities for environmental matters and other contingencies when it is probable that a liability has been incurred and the amount of the liability can reasonably be estimated . if the contingency is resolved for an amount greater or less than the accrual , or our share of the contingency increases or decreases , or other assumptions relevant to the development of the estimate were to change , we would recognize an additional expense or benefit in income in the period that the determination was made . taxes we account for income taxes in accordance with gaap . gaap establishes financial accounting and reporting standards for the effects of income taxes that result from an enterprise 's activities during the current and preceding years . it requires an asset-and-liability approach to financial accounting and reporting of income taxes . deferred tax assets are recorded for net operating losses and temporary differences between the book and tax basis of assets and liabilities expected to produce tax deductions in future periods . the ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the tax periods in which those deferred tax assets would be deductible . a valuation allowance is taken when necessary to reduce deferred tax assets to the amount expected to be realized . when determining the amount of net deferred tax assets that are more likely than not to be realized , we assess all available positive and negative evidence . this evidence includes , but is not limited to , scheduled reversal of deferred tax liabilities , prior earnings history , projected future earnings , carry-back and carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset . the weight given to the positive and negative evidence is commensurate with the extent the evidence may be objectively verified . as such , it is generally difficult for positive evidence regarding projected future taxable income ( exclusive of reversing taxable temporary differences and carryforwards ) to outweigh objective negative evidence such as our recent financial reporting loss for the year ended june 30 , 2018. therefore , we recorded a valuation allowance of $ 76,500 against our net u.s. deferred tax assets during the year ended june 30 , 2018. the timing of when , and the extent to which , a valuation allowance is recognized , is subjective . initially , due to the various factors that occurred in the fourth quarter of fiscal 2018 , including substantial penalties for delays in supplying products and incurring substantial expenses to address the issues that led to the impairment charges taken during the year , as well as retaining financial and legal advisors to assist us in dealing with the various challenges that the company is currently facing , including legal advisors retained in connection with various ongoing legal proceedings , we determined to record this valuation allowance during the fourth quarter of fiscal 2018. however , after weighing the information available to us at the time that our third quarter financial statements were issued , we have determined , with the assistance of our advisors , that it is reasonable to conclude that it was more likely than not that a substantial portion of the valuation allowance should have been

